A Phase 3 interventional study of GB-0998 and Placebo of GB-0998 in Polymyositis and Dermatomyositis, sponsored by Japan Blood Products Organization. Completed at 1 site in Japan. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-11-05.
Sponsored by Japan Blood Products Organization · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Dermatomyositis with a site in Japan — 7 open to participants now, 8 under way, 4 of them phase 3. Dermatomyositis · Japan.
Among the 18 studies in Dermatomyositis with a site in Japan, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2006, is one of 9 in phase 3, and was the 1st registered.
184 studies on the registry are indexed under Dermatomyositis; 62 are open to participants now.
Browse Dermatomyositis studies →7 of the 18 studies in Dermatomyositis with a site in Japan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Japan, United States, Canada and 7 more countries
Ages 18–70
Pfizer · Sites in Japan, United States, Argentina and 9 more countries
Ages 18+
Chugai Pharmaceutical · Sites in Japan, United States, Australia and 17 more countries
Ages 18–85
AstraZeneca · Sites in Japan, United States, Argentina and 26 more countries
Ages 18–75
Pfizer · Sites in Japan, United States, Argentina and 17 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 49 Dermatomyositis studies recruiting now, 24 (49%) set no upper age limit and 15 (31%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 16 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 12
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 35 across 130 interventional studies indexed under Dermatomyositis.
Median enrollment 144 across the 17 interventional studies, 179 across the 1 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 18 have an industry lead sponsor. The 10 most frequent:
Japan Blood Products Organization is the lead sponsor of 4 studies on the registry; none are open to participants now.
Japan Blood Products Organization has 1 study filed under Dermatomyositis — fewer than ten, so there is no comparison to draw.
2 of the studies in Dermatomyositis with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Dermatomyositis with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled trial will carry out to assess the efficacy of GB-0998 in the treatment of the steroid-resistant polymyositis and dermatomyositis based on the changes in manual muscle strength (MMT) scores as primary endpoint, and in addition, to assess the safety of GB-0998.
184 studies on the registry are indexed under Dermatomyositis; 62 are open to participants now.
This study's enrollment of 26 is below the median of 35 across 130 interventional studies indexed under Dermatomyositis.
Browse Dermatomyositis studies →Japan Blood Products Organization is the lead sponsor of 4 studies on the registry; none are open to participants now.
Compared within Dermatomyositis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Polymyositis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GB-0998
Drug: Placebo of GB-0998
8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
Also known as: High-dose intravenous immunoglobulin, Venoglobulin-IH
8 mL/kg per day is intravenously administered for five successive days
Changes in manual muscle strength (MMT) scores
Time frame: 8 weeks
Changes in the serum levels of creatine kinase (CK) and total scores of activities of daily living (ADL)
Time frame: 8 weeks
Adverse events and laboratory tests
Time frame: 8 weeks
The record gives a start of Jun 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GB-0998
Japan Blood Products Organization